Abstract
There is a number of antidepressants (ADs) which prevent reabsorption of neurotransmitters in the body. Known together as reuptake inhibitors, they prevent the reuptake of one or some neurotransmitters so that the majority of them is present and active in the brain. Selective serotonin reuptake inhibitors (SSRIs) work at the expense of specific inhibition of serotonin reuptake. Such new SSRIs fluoxetine (FXT), are effective for treatment of depressive disorders in most cases of schizophrenia. The effectiveness of SSRIs is not immediate; therefore, medication can take up to several weeks to be fully effective. FXT is one of the top ten prescribed antidepressants. FXT is prescribed in cases of depressive disorders in adults and adolescents [1], obsessive-compulsive and anxiety-depressive disorders [2], as well as for the therapy of bulimia nervosa [3]. Pharmacogenetic markers of FXT safety are being actively studied. Some pharmacogenetic markers of therapy safety have been established: genes of serotonin receptor isoforms and its transporters (HTR1A, HTR1B, SCL6A4).
Highlights
Fluoxetine (FXT) is a representative of the propylamine derivatives, an antidepresant from the selective serotonin reuptake inhibitors (SSRIs) class
According to a 2018 meta-analysis, FXT was characterized by better tolerability and the greatest commitment of patients to therapy, this drug was proven to be in the group of the least effective antidepressants [4]
The aim of this study is to review of pharmacogenetics studies of fluoxetine
Summary
Fluoxetine (FXT) is a representative of the propylamine derivatives, an antidepresant from the selective serotonin reuptake inhibitors (SSRIs) class. FXT was approved by the FDA as an antidepressant in December 1987 [5]. It can be used in panic and premenstrual dysphoric disorders. FXT has an evident stimulating effect (including the fact that it causes insomnia and agitation more often than other SSRIs) [8]. It is characterized by a drug withdrawal syndrome, the symptoms, mistaken for a relapse of depression [9]. FXT has ADRs typical of its class: abnormal dreaming, dry mouth, dyspepsia, nausea, sweating, tremor and yawning, anorexia
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
